(firstQuint)Phase II Study of Revlimid, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma.

 This is a phase II single institution trial in patients with newly diagnosed multiple myeloma.

 Revlimid(R) 25 mg p.

o.

 daily on days 1-21 of each 28-day cycle.

 Cyclophosphamide 50 mg p.

o.

 BID daily on days 1-21 of each 28-day cycle.

 Prednisone 50 mg p.

o.

 Q.

O.

D.

.

.

 Phase II Study of Revlimid, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma@highlight

The purpose of this study to explore the combination of Revlimid(R), oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

